Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.74 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | BRAF | P15056 | 1/20 | 0.74 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.74 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858917 | 1.00 | MAP2K1 (0.74) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL24223772 | 0.87 | MAP2K1 (0.81) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL20193751 | 0.87 | MAP2K1 (0.81) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL25736933 | 0.87 | MAP2K1 (0.81) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL15424103 | 0.87 | MAP2K1 (0.81) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL4855302 | 0.86 | MAP2K1 (0.80) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL12582182 | 0.85 | MAP2K1 (0.78) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL4857208 | 0.85 | MAP2K1 (0.78) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL18457665 | 0.85 | MAP2K1 (0.78) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 | |
| SCHEMBL4851636 | 0.85 | MAP2K1 (0.77) | MAP2K1MAP2K2MAPK1BRAFMAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ERBB2, ERBB3, AXL | MAP2K1 1600/4885MAP2K2 974/4885MAPK1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.